Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above Two Hundred Day Moving Average – Time to Sell?

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $24.95 and traded as high as $36.43. Assembly Biosciences shares last traded at $34.60, with a volume of 55,293 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ASMB shares. Mizuho set a $40.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Guggenheim increased their target price on Assembly Biosciences from $31.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, September 8th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. Finally, Citizens Jmp started coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Price Performance

The stock’s 50 day moving average is $32.99 and its two-hundred day moving average is $25.14. The firm has a market capitalization of $513.83 million, a P/E ratio of -6.78 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. As a group, equities research analysts expect that Assembly Biosciences, Inc. will post -6.87 EPS for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds have recently added to or reduced their stakes in ASMB. Bank of America Corp DE grew its position in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,319 shares during the period. Qube Research & Technologies Ltd acquired a new position in Assembly Biosciences during the third quarter valued at approximately $282,000. American Century Companies Inc. bought a new stake in Assembly Biosciences in the first quarter valued at approximately $113,000. Palumbo Wealth Management LLC raised its holdings in Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 681 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Assembly Biosciences in the 3rd quarter valued at $485,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.